Beovu, manufactured and distributed by Novartis, achieved FDA approval on Oct. 8, 2019.
FDA approval was based on two extensive prospective randomized masked clinical trials named HAWK and HARRIER. These clinical trials included more than 1,800 patients enrolled and followed for 96 months in 400 centers globally by the world’s top retina specialists.
Beovu (brolucizumab) is a lower molecular weight anti-VEGF molecule that allows a higher concentration of drug to reach the retina and choroid after an intravitreal injection. The HAWK and HARRIER studies confirmed the anticipated benefits
Uncategorized